Clinical characteristics of the PMBL cohort (N = 95)
| Clinical characteristic . | n (%) . |
|---|---|
| Sex | |
| Female | 54 (56.8) |
| Male | 41 (43.2) |
| Age, median (range), y | 34 (13-79) |
| Stage | |
| I/II | 70 (73.7) |
| III/IV | 24 (25.3) |
| NA | 1 (1) |
| Biopsy site | |
| Mediastinum | 59 (62.1) |
| Local or cervical lymph nodes, lung | 29 (30.5) |
| Inguinal lymph node, paraspinal L1 | 2 (2.1) |
| NA | 5 (5.3) |
| IPI group | |
| Low | 41 (43.1) |
| Intermediate | 39 (41.1) |
| High | 11 (11.6) |
| NA | 4 (4.2) |
| Bulky disease (>10 cm) | |
| Yes | 70 (73.7) |
| No | 24 (25.3) |
| NA | 1 (1) |
| Rituximab-containing therapy | |
| Yes | 59 (62.1) |
| No | 33 (34.7) |
| NA | 3 (3.2) |
| Clinical characteristic . | n (%) . |
|---|---|
| Sex | |
| Female | 54 (56.8) |
| Male | 41 (43.2) |
| Age, median (range), y | 34 (13-79) |
| Stage | |
| I/II | 70 (73.7) |
| III/IV | 24 (25.3) |
| NA | 1 (1) |
| Biopsy site | |
| Mediastinum | 59 (62.1) |
| Local or cervical lymph nodes, lung | 29 (30.5) |
| Inguinal lymph node, paraspinal L1 | 2 (2.1) |
| NA | 5 (5.3) |
| IPI group | |
| Low | 41 (43.1) |
| Intermediate | 39 (41.1) |
| High | 11 (11.6) |
| NA | 4 (4.2) |
| Bulky disease (>10 cm) | |
| Yes | 70 (73.7) |
| No | 24 (25.3) |
| NA | 1 (1) |
| Rituximab-containing therapy | |
| Yes | 59 (62.1) |
| No | 33 (34.7) |
| NA | 3 (3.2) |
IPI, International prognostic index; NA, not available.